Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy.

Raymond E, Faivre S, Armand JP.

Drugs. 2000;60 Suppl 1:15-23; discussion 41-2. Review.

PMID:
11129168
2.
3.

Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents.

Ciardiello F.

Drugs. 2000;60 Suppl 1:25-32; discussion 41-2. Review.

PMID:
11129169
4.

Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents.

Ghosh S, Liu XP, Zheng Y, Uckun FM.

Curr Cancer Drug Targets. 2001 Aug;1(2):129-40. Review.

PMID:
12188886
5.

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?

Normanno N, Maiello MR, De Luca A.

J Cell Physiol. 2003 Jan;194(1):13-9. Review.

PMID:
12447985
6.

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Harding J, Burtness B.

Drugs Today (Barc). 2005 Feb;41(2):107-27. Review.

PMID:
15821783
7.

The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.

Ritter CA, Arteaga CL.

Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11. Review.

PMID:
12644979
8.

The ErbB/HER family of protein-tyrosine kinases and cancer.

Roskoski R Jr.

Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20. Review.

PMID:
24269963
9.

Epidermal growth factor receptor inhibition strategies in oncology.

Harari PM.

Endocr Relat Cancer. 2004 Dec;11(4):689-708. Review.

10.

Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.

Vokes EE, Chu E.

Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25. Review.

PMID:
16736979
11.

Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.

Tiseo M, Loprevite M, Ardizzoni A.

Curr Med Chem Anticancer Agents. 2004 Mar;4(2):139-48. Review.

PMID:
15032719
12.

The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.

Janmaat ML, Giaccone G.

Drugs Today (Barc). 2003;39 Suppl C:61-80. Review.

PMID:
14988746
13.

Epidermal growth factor receptor: pathway, therapies, and pipeline.

Goffin JR, Zbuk K.

Clin Ther. 2013 Sep;35(9):1282-303. doi: 10.1016/j.clinthera.2013.08.007. Review.

PMID:
24054705
14.

The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer.

Averbuch SD.

Clin Lung Cancer. 2003 Sep;5 Suppl 1:S5-S10. Review.

PMID:
14641988
15.
16.
17.

Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.

Bianco R, Damiano V, Gelardi T, Daniele G, Ciardiello F, Tortora G.

Curr Pharm Des. 2007;13(33):3358-67. Review.

PMID:
18045190
18.

A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

Ciardiello F, Tortora G.

Clin Cancer Res. 2001 Oct;7(10):2958-70. Review.

19.

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

Albanell J, Rojo F, Baselga J.

Semin Oncol. 2001 Oct;28(5 Suppl 16):56-66. Review.

PMID:
11706397
20.

Anti-epidermal growth factor receptor drugs in cancer therapy.

Ciardiello F, Tortora G.

Expert Opin Investig Drugs. 2002 Jun;11(6):755-68. Review.

PMID:
12036420

Supplemental Content

Support Center